Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells.

[severe combined immunodeficiency]

Adoptive immunotherapy with antigen-specific T cells has shown promise for the treatment of malignancies . However , infused T cells are unable to redirect resident T cells , limiting potential benefit . While the infusion of bispecific T -cell engagers can redirect resident T cells to tumors , these molecules have a short half -life , and do not self amplify . To overcome these limitations , we generated T cells expressing a secretable T -cell engager specific for CD 3 and EphA 2 , an antigen expressed on a broad range of human tumors (EphA 2 -ENG T cells ). EphA 2 -ENG T cells were activated and recognized tumor cells in an antigen-dependent manner , redirected bystander T cells to tumor cells , and had potent antitumor activity in glioma and lung cancer severe combined immunodeficiency (SCID ) xenograft models associated with a significant survival benefit . This new class of tumor -specific T cells , with the unique ability to redirect bystander T cells , may be a promising alternative to current immunotherapies for cancer .Molecular Therapy (2014 ); doi :10 .1038 /mt .2014 .156 .

Diseases
Validation

Diseases presenting "broad range" symptom

acute rheumatic fever

congenital toxoplasmosis

cowden syndrome

cystinuria

dystrophic epidermolysis bullosa

gm1 gangliosidosis

hereditary cerebral hemorrhage with amyloidosis

kallmann syndrome

neuralgic amyotrophy

severe combined immunodeficiency

typhoid

waldenström macroglobulinemia

well-differentiated liposarcoma

You can validate or delete this automatically detected symptom